Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers. Senior Personal Finance Correspondent Sharon ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

"We see opportunity within our unique snacking portfolio," Tom McGough, co‐chief operating officer with Conagra Brands, told ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs, for the second annual round of drug price ...

Noom releases a significant update of its innovative GLP-1 companion to improve medication persistence and adherence while ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

"The GLP-1 class is the most important category by far, and they're going to have oral data for a pill, I think, sometime in the first half of this year [toward] the spring, summer timeframe," he ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...